#Canada #Montreal #Nanoscope Therapeutics #optogenetic therapy #Retina

Nanoscope Therapeutics to Present at the ASRS Annual Scientific Meeting

Nanoscope Therapeutics, a pioneering biotechnology firm dedicated to creating and delivering innovative therapies for those suffering from retinal degeneration, is gearing up for a significant presentation at the 44th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS). This much-anticipated event will occur from July 15 to 18, 2026, at the Palais des Congrès de Montréal, Canada. The company will reveal clinical trial data demonstrating the potential benefits of its cutting-edge optogenetic therapies aimed at restoring vision for patients experiencing photoreceptor loss.

Focus on Vision Restoration: A Glimpse into Nanoscope's Research

During the upcoming ASRS meeting, Nanoscope will unveil two key presentations focusing on their optogenetic therapy programs.

1. Vision Improvement with Sonpiretigene Isteparvovec
This presentation will mark the unveiling of the first direct-to-phase 2 randomized, controlled trial. Dr. Jordi Monés will discuss the implications of the study that explores how optogenetic therapy can bring about significant vision improvement in patients with age-related macular degeneration (AMD), particularly those suffering from geographic atrophy (GA).

2. Durable Vision Improvement with MCO-010
Dr. Benjamin Bakall will present compelling long-term data from the RESTORE Phase 2b/3 trial focusing on MCO-010, designed for retinitis pigmentosa (RP). The paper-on-demand presentation will shed light on the three-year follow-up results, focusing on the sustained effect of this groundbreaking treatment.

The MCO Platform: Revolutionizing Retinal Treatments

At the core of Nanoscope Therapeutics is their multi-characteristic opsin (MCO) platform, a one-time, in-office intravitreal therapy designed to address various degenerative retinal conditions, including RP, Stargardt disease, and GA. MCO therapy uniquely operates by activating the remaining visual circuitry after photoreceptor loss, effectively re-engaging retinal cells that become light-sensitive.

The treatment comes with significant advantages: there are no requirements for genetic testing, invasive surgical procedures, or repeated dosing, making it highly applicable within existing retinal care practices. This ease of application enables broader accessibility for patients in need.

A Bright Future for Patients with Retinal Diseases

Nanoscope is at the forefront of advancing optogenetic therapies as a viable treatment option for millions of individuals affected by retinal degenerative diseases. Following promising results from the RESTORE Phase 2b/3 trial, the company has submitted a Biologics Licensing Application (BLA) to the FDA for MCO-010. If approved, this therapy could set a new standard for care among RP patients with its one-time injection protocol that does not necessitate detailed genetic evaluation.

The company has also reported encouraging findings in their STARLIGHT Phase 2 clinical trial for MCO-010 treating Stargardt disease, with plans to initiate a Phase 3 trial later this year. MCO-010 has received various designations, including Fast Track and Orphan Drug status from the FDA, along with an RMAT designation for Stargardt. Additionally, the European Medicines Agency (EMA) recognizes the treatment for multiple inherited retinal dystrophies.

Nanoscope's journey continues to break barriers, extending their research efforts towards developing optogenetic treatments for Leber congenital amaurosis and establishing a Phase 2 program for geographic atrophy, also set to commence in 2026. With a strong commitment to innovation, Nanoscope Therapeutics is paving the way for a new era in vision restoration, transforming the lives of those hindered by sight loss.

For further information, please contact Nanoscope Therapeutics at (817) 857-1186 or via email at [email protected].